PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.88), $0.40 worse than the analyst estimate of ($1.48). Revenue for the quarter came in at $220.4 million versus the consensus estimate of $205.47 million.

GUIDANCE:

PTC Therapeutics sees FY2023 revenue of $0.94-1 billion vs $0.87 billion estimate.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.